Microbix’s Clot-Buster Drug Project Advances

Microbix Biosystems Inc. announces that its funding and commercialization partner, Sequel Pharma, LLC, has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization for production of the active ingredient of Kinlytic® urokinase, a biologic drug for dissolving blood clots.